The Cabinet Committee on Economic Affairs (CCEA) has approved foreign investments in Aurobindo Pharma. The approval has been given for Qualified Institutional Buyers (QIBs) to infuse fresh equity of up to 7% amounting to about Rs 2,165 crore into the company. The existing FII shareholding is 27.32% in the company.
This will enable the company to expand its operations in the areas of anti infective, cardiovascular and central nervous system related ingredients. The company employs more than 9500 professionals from 26 countries.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1676.00 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1235.05 |
| Zydus Lifesciences | 941.20 |
| Lupin | 2330.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: